Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Hester Biosciences's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was ₹225 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹1,003 Mil.
Hester Biosciences (BOM:524669) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Hester Biosciences Selling, General, & Admin. Expense Related Terms
Hester Biosciences Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Hester Biosciences's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hester Biosciences Selling, General, & Admin. Expense Chart
BOM:524669 vs ZTS: Selling, General, & Admin. Expense Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hester Biosciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hester Biosciences Selling, General, & Admin. Expense vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hester Biosciences's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Hester Biosciences's Selling, General, & Admin. Expense falls into.
Hester Biosciences Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,003 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of ₹1,003 Mil mean?
Hester Biosciences (BOM:524669) has a Selling, General, & Admin. Expense of ₹1,003 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Hester Biosciences and its competitors.
Is Hester Biosciences' Selling, General, & Admin. Expense too high?
Hester Biosciences' current Selling, General, & Admin. Expense is ₹1,003 Mil. Overall, Hester Biosciences has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' Selling, General, & Admin. Expense compare to ZTS?
Hester Biosciences' Selling, General, & Admin. Expense of ₹1,003 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Hester Biosciences and its competitors. Hester Biosciences's current Selling, General, & Admin. Expense is ₹1,003 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,884.20, compared to a current price of ₹2,187.10 — trading 16.1% above its estimated fair value. The current Selling, General, & Admin. Expense is ₹1,003 Mil. Hester Biosciences' overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current Selling, General, & Admin. Expense is ₹1,003 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hester Biosciences (BOM:524669) Overvalued in 2026?
Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued.
The current stock price of ₹2,187.10 is trading 16.1% above its estimated GF Value™ of ₹1,884.20.
GuruFocus considers Hester Biosciences to be Modestly Overvalued.
Key valuation signals for BOM:524669:
Selling, General, & Admin. Expense: ₹1,003 Mil
GF Value™: ₹1,884.20 vs. price of ₹2,187.10 (16.1% above fair value)
No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
77GF Score
Get the complete analysis for BOM:524669
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524669 has been successfully added to your 
